Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 69Neoplasms 20Neoplasm Metastasis 12Brain Neoplasms 4Stomach Neoplasms 2Recurrence 2Osteitis Deformans 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER-2 Gene Amplification 1Glioma 1Glioblastoma 1Diarrhea 1Carcinoma 1Breast Diseases 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

pyrotinib 3Capecitabine 3Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × HER2 Positive Metastatic Breast Cancer × Lapatinib × Clear all
NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡